1/12
11:05 am
biib
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
Low
Report
Biogen Receives European Commission Approval for High Dose Regimen of SPINRAZA® (nusinersen) for Spinal Muscular Atrophy
1/10
03:22 pm
biib
Here's What Analysts Think About Biogen Inc. (BIIB) [Yahoo! Finance]
Low
Report
Here's What Analysts Think About Biogen Inc. (BIIB) [Yahoo! Finance]
1/8
10:04 am
biib
Biogen (NASDAQ:BIIB) was given a new $190.00 price target on by analysts at Truist Financial Corporation.
Low
Report
Biogen (NASDAQ:BIIB) was given a new $190.00 price target on by analysts at Truist Financial Corporation.
1/8
08:42 am
biib
Biogen (NASDAQ:BIIB) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Low
Report
Biogen (NASDAQ:BIIB) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
1/7
07:08 am
biib
Biogen (NASDAQ:BIIB) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Biogen (NASDAQ:BIIB) had its "neutral" rating reaffirmed by analysts at Citigroup Inc..
1/6
07:01 pm
biib
Biogen (NASDAQ:BIIB) was given a new $185.00 price target on by analysts at UBS Group AG.
Low
Report
Biogen (NASDAQ:BIIB) was given a new $185.00 price target on by analysts at UBS Group AG.
1/5
10:07 pm
biib
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China [Yahoo! Finance]
Medium
Report
Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease Accepted in China [Yahoo! Finance]
12/30
09:01 am
biib
Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge [Seeking Alpha]
Low
Report
Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge [Seeking Alpha]
12/22
11:50 am
biib
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS [Yahoo! Finance]
Low
Report
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS [Yahoo! Finance]
12/22
11:20 am
biib
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
Low
Report
The Journal of the American Medical Association (JAMA) Neurology Publishes Long Term Results from the QALSODY Phase 3 VALOR Study and its Open-Label Extension in SOD1-ALS
12/19
09:18 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at BMO Capital Markets from $150.00 to $165.00. They now have a "market perform" rating on the stock.
Medium
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at BMO Capital Markets from $150.00 to $165.00. They now have a "market perform" rating on the stock.
12/19
05:24 am
biib
HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress [Yahoo! Finance]
Medium
Report
HSBC Downgrades Biogen Inc. (BIIB) to Reduce Despite Pipeline Progress [Yahoo! Finance]
12/12
12:01 pm
biib
Biogen (NASDAQ:BIIB) was given a new $156.00 price target on by analysts at Morgan Stanley.
Low
Report
Biogen (NASDAQ:BIIB) was given a new $156.00 price target on by analysts at Morgan Stanley.
12/11
07:14 am
biib
Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS [Yahoo! Finance]
Low
Report
Canadian HTA Assessments Recognize Therapeutic Value of QALSODY™ (tofersen injection) and its Potential to Modify Disease Progression in Individuals Living with SOD1-ALS [Yahoo! Finance]
12/11
06:28 am
biib
Biogen (NASDAQ:BIIB) was downgraded by analysts at Hsbc Global Res from a "hold" rating to a "moderate sell" rating.
Low
Report
Biogen (NASDAQ:BIIB) was downgraded by analysts at Hsbc Global Res from a "hold" rating to a "moderate sell" rating.
12/10
09:17 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Wells Fargo & Company from $155.00 to $190.00. They now have an "equal weight" rating on the stock.
Low
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Wells Fargo & Company from $155.00 to $190.00. They now have an "equal weight" rating on the stock.
12/10
07:01 am
biib
Biogen (NASDAQ:BIIB) was downgraded by analysts at HSBC Holdings plc from a "hold" rating to a "reduce" rating.
Medium
Report
Biogen (NASDAQ:BIIB) was downgraded by analysts at HSBC Holdings plc from a "hold" rating to a "reduce" rating.
12/5
09:00 am
biib
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
Low
Report
Biogen and Stoke Therapeutics Present Data that Further Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 2025 American Epilepsy Society (AES) Annual Meeting
12/3
06:10 pm
biib
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
Low
Report
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025
12/2
04:40 pm
biib
New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aß Protofibrils in CSF
Low
Report
New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aß Protofibrils in CSF
12/1
07:48 am
biib
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting [Yahoo! Finance]
Low
Report
Stoke Therapeutics and Biogen Announce Presentations at the 2025 American Epilepsy Society Annual Meeting [Yahoo! Finance]
11/28
09:18 am
biib
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Jefferies Financial Group Inc. from $190.00 to $210.00. They now have a "buy" rating on the stock.
Low
Report
Biogen (NASDAQ:BIIB) had its price target raised by analysts at Jefferies Financial Group Inc. from $190.00 to $210.00. They now have a "buy" rating on the stock.
11/25
07:30 am
biib
Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Low
Report
Eisai Completes Rolling Submission to U.S. FDA for LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
11/24
07:30 am
biib
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
Medium
Report
Biogen and Dayra Therapeutics Announce Research Collaboration to Discover and Develop Oral Macrocyclic Peptides for a Range of Immunological Conditions
11/21
08:11 am
biib
Biogen (NASDAQ:BIIB) had its "neutral" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Biogen (NASDAQ:BIIB) had its "neutral" rating reaffirmed by analysts at Piper Sandler.